Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 5/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.40 |
| ▸ | MIF | P14174 | 4/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | BACH1 | O14867 | 1/20 | 0.38 |
| ▸ | MAFK | O60675 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9531670 | 0.95 | — | — | |
| SCHEMBL3109402 | 0.79 | MIF (0.52) | KEAP1NFE2L2MIFNAAALMNA | |
| Ethane SCHEMBL668882 | 0.78 | LMNA (0.38) | LMNAALDH1A1ALKBH5SUCNR1EGLN1 | |
| SCHEMBL1805417 | 0.77 | MIF (0.56) | KEAP1NFE2L2MIFNAAALMNA | |
| Hydrochloric Acid SCHEMBL9698829 | 0.76 | MIF (0.54) | KEAP1NFE2L2MIFNAAALMNA | |
| SCHEMBL1364810 | 0.73 | — | — | |
| Ethyl Isothiocyanate SCHEMBL1811949 | 0.72 | — | — | |
| SCHEMBL1201008 | 0.72 | — | — | |
| Water SCHEMBL28001085 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL9459532 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330252-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3075248-B1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES INC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10117904-B2 | Use of anti-bacterial agents for the treatment of epithelial-related conditions | SIGNUM BIOSCIENCES, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3330252-A2 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | Signum Biosciences, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2963012-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20170368011-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170049841-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM DERMALOGIX, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20160361283-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM DERMALOGIX, INC. | 2016-12-15 | — | — | US | disclosed |
| EP-2963012-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | Signum Biosciences, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2362866-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20130310559-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8372884-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. | 2013-02-12 | — | — | US | disclosed |
| EP-2498603-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | Signum Biosciences, Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2362866-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | Signum Biosciences, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2011060330-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118265-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | SIGNUM DERMALOGIX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM BIOSCIENCES, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010056778-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049841-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | EPCAM, ELANE, CFTR | KEAP1 95/4885NFE2L2 346/4885MIF 513/4885 |
| US-20110118265-A1 | USE OF ANTI-BACTERIAL AGENTS FOR THE TREATMENT OF EPITHELIAL-RELATED CONDITIONS | EPCAM, ELANE, CFTR | KEAP1 95/4885NFE2L2 346/4885MIF 513/4885 |
| US-10117904-B2 | Use of anti-bacterial agents for the treatment of epithelial-related conditions | EPCAM, ELANE, CFTR | KEAP1 95/4885NFE2L2 346/4885MIF 513/4885 |
| US-20160361283-A1 | Isoprenyl Compounds and Methods Thereof | ALOX15B, ALOX15, ALOX5 | KEAP1 28/4885NFE2L2 172/4885MIF 174/4885 |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | ALOX15B, ALOX15, ALOX5 | KEAP1 28/4885NFE2L2 172/4885MIF 174/4885 |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | ALOX15B, ALOX15, ALOX5 | KEAP1 28/4885NFE2L2 172/4885MIF 174/4885 |
| US-20130310559-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | ALOX15B, ALOX15, ALOX5 | KEAP1 28/4885NFE2L2 172/4885MIF 174/4885 |
| US-20170368011-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | ALOX15B, ALOX15, ALOX5 | KEAP1 28/4885NFE2L2 172/4885MIF 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.